Schizophrenia: From developmental deviance to dopamine dysregulation

European Neuropsychopharmacology

Volumn 18, Issue SUPPL. 3, 2008, Pages

  Murray, Robin M ^a   Lappin, Julia ^a   Di Forti, Marta ^a  

^a KING'S COLLEGE LONDON   (United Kingdom)

Author keywords

CBT; Dopamine; Risk factors; Schizophrenia

Indexed keywords

AMPHETAMINE; CANNABIS; DOPAMINE 1 RECEPTOR; DOPAMINE 2 RECEPTOR; METHAMPHETAMINE; NEUROLEPTIC AGENT; PSYCHOSTIMULANT AGENT;

AMNESIA; ARTICLE; ATTENTION DEFICIT DISORDER; BLURRED VISION; CANNABIS ADDICTION; COGNITIVE DEFECT; COGNITIVE THERAPY; CONFUSION; CONSTIPATION; CORPUS STRIATUM; DOPAMINE BRAIN LEVEL; DOPAMINE RELEASE; DOPAMINERGIC SYSTEM; DRUG UTILIZATION; ENVIRONMENTAL FACTOR; FRONTAL CORTEX; HEART RATE; HUMAN; HYPOTHESIS; MENTAL CONCENTRATION; MENTAL DISEASE; NERVOUS SYSTEM DEVELOPMENT; NONHUMAN; PRIORITY JOURNAL; PROTEIN EXPRESSION; RISK FACTOR; SCHIZOPHRENIA; SEDATION; SIDE EFFECT; SOCIAL ISOLATION; SOCIAL PHOBIA; SOCIAL STRESS; SWEATING; SYMPTOM; URINE RETENTION; XEROSTOMIA;

ANIMALS; DOPAMINE; HUMANS; SCHIZOPHRENIA; SCHIZOPHRENIC PSYCHOLOGY; SOCIAL BEHAVIOR;

EID: 50049107823     PISSN: 0924977X     EISSN: None     Source Type: Journal    
DOI: 10.1016/j.euroneuro.2008.04.002     Document Type: Article

References (63)

1. Addington J., and Addington D. Positive and negative symptoms of schizophrenia. Their course and relationship over time. Schizophr. Res. 5 (1991) 51-59
2. Allardyce J., Morrison G., Van Os J., Kelly J., Murray R.M., and McCreadie R.G. Schizophrenia is not disappearing in south-west Scotland. Br. J. Psychiatry 177 (2000) 38-41
3. Andréasson S., Allebeck P., Engström A., and Rydberg U. Cannabis and schizophrenia. Lancet 1 (1988) 1000-1001
4. Arseneault L., Cannon M., Poulton R., Murray R., Caspi A., and Moffitt T.E. Cannabis use in adolescence and risk for adult psychosis: longitudinal prospective study. BMJ. 325 (2002) 1212-1213
5. Berridge K.C., and Robinson T.E. What is the role of dopamine in reward: hedonic impact, reward learning, or incentive salience?. Brain Res. Rev. 28 (1998) 309-369
6. Berton O., McClung C.A., DiLeone R.J., Krishnan V., Renthal W., Russo S.J., Graham D., Tsankova N.M., Bolanos C.A., Rios M., Monteggia L.M., Self D.W., and Nestler E.J. Essential role of BDNF in the mesolimbic dopamine pathway in social defeat stress. Science 311 (2006) 864-868
7. Bhugra D. Migration and schizophrenia. Acta. Psychiatrica. Scandinavica Suppl. 407 (2000) 68-73
8. Blackwood D.H.R., Fordyce A., Walker M.T., St. Clair D.M., Porteous D.J., and Muir W.J. Schizophrenia and affective disorders-cosegregation with a translocation at chromosome 1q42 that directly disrupts brain-expressed genes: clinical and P300 findings in a family. Am. J. Hum. Genet. 69 (2001) 428-433
9. Boydell J., van Os J., McKenzie K., Allardyce J., Goel R., McCreadie R.G., and Murray R.M. Incidence of schizophrenia in ethnic minorities in London: ecological study into interactions with environment. BMJ 323 (2001) 1336-1338
10. Breier A., Su T.-P., Saunders R., Carson R.E., Kolachana B.S., de Bartolomeis A., Weinberger D.R., Weisenfeld N., Malhotra A.K., Eckelman W.C., and Pickar D. Schizophrenia is associated with elevated amphetamine-induced synaptic dopamine concentrations: evidence from a novel positron emission tomography method. Proc. Natl. Acad. Sci. 94 (1997) 2569-2574
11. Cannon M., Jones P.B., and Murray R.M. Obstetric complications and schizophrenia: historical and meta-analytic review. Am. J. Psychiatry 159 (2002) 1080-1092
12. Cannon M., Caspi A., Moffitt T.E., Harrington H., Taylor A., Murray R.M., and Poulton R. Evidence for early-childhood, pan-developmental impairment specific to schizophreniform disorder: results from a longitudinal birth cohort. Arch. Gen. Psychiatry 59 (2002) 449-456
13. Cannon M., Moffitt T.E., Caspi A., Murray R.M., Harrington H., and Poulton R. Neuropsychological performance at the age of 13 years and adult schizophreniform disorder: prospective birth cohort study. Br. J. Psychiatry 189 (2006) 463-464
14. Caspi A., Moffitt T.E., Cannon M., McClay J., Murray R., Harrington H., Taylor A., Arseneault L., Williams B., Braithwaite A., Poulton R., and Craig I.W. Moderation of the effect of adolescent-onset cannabis use on adult psychosis by a functional polymorphism in the catechol-O-methyltransferase gene: longitudinal evidence of a gene X environment interaction. Biol. Psychiatry 57 (2005) 1117-1127
15. Chen C.K., Lin S.K., Sham P.C., Ball D., Loh E.W., Hsiao C.C., Chiang Y.L., Ree S.C., Lee C.H., and Murray R.M. Pre-morbid characteristics and co-morbidity of methamphetamine users with and without psychosis. Psychol. Med. 33 (2003) 1407-1414
16. Connell P.H. Amphetamine psychosis. Maudsley Monographs, No. 5 (1958), Oxford University Press, London
17. Cornblatt B., Obuchowski M., Roberts S., Pollack S., and Erlenmeyer-Kimling L. Cognitive and behavioral precursors of schizophrenia. Dev. Psychopathol. 11 (1999) 487-508
18. Di Forte M., Lappin J.M., and Murray R.M. Risk factors for schizophrenia-all roads lead to dopamine. Eur. Neuropsychopharmacol. 17 (2007) S101-S107
19. Ekelund J., Hovatta I., Parker A., Paunio T., Varilo T., Martin R., Suhonen J., Ellonen P., Chan G., Sinsheimer J.S., Sobel E., Juvonen H., Arajarvi R., Partonen T., Suvisaari J., Lönnqvist J., Meyer J., and Peltonen L. Chromosome 1 loci in Finnish schizophrenia families. Hum. Mol. Genet. 10 (2001) 1611-1617
20. Erlenmeyer-Kimling L. Early neurobehavioral deficits as phenotypic indicators of the schizophrenia genotype and predictors of later psychosis. Am. J. Med. Genet. 105 (2001) 23-24
21. Fergusson D.M., Horwood L.J., and Swain-Campbell N.R. Cannabis dependence and psychotic symptoms in young people. Psychol. Med. 33 (2003) 15-21
22. Hall F.S., Wilkinson L.S., Humby T., Inglis W., Kendall D.A., Marsden C.A., and Robbins T.W. Isolation rearing in rats: pre- and postsynaptic changes in striatal dopaminergic systems. Pharmacol. Biochem. Behav. 59 (1998) 859-872
23. Harrison P.J., and Owen M.J. Genes for schizophrenia? Recent findings and their pathophysiological implications. Lancet. 361 (2003) 417-419
24. Harrison G., Owens D., Holton A., Neilson D., and Boot D. A prospective study of severe mental disorder in Afro-Caribbean patients. Psychol. Med. 18 (1988) 643-657
25. Henquet C., Murray R., Linszen D., and van Os J. The environment and schizophrenia: the role of cannabis use. Schizophr. Bull. 31 (2005) 608-612
26. Henquet C., Rosa A., Krabbendam L., Papiol S., Fananás L., Drukker M., Ramaekers J.G., and van Os J. An experimental study of catechol-O-methyltransferase val(158)met moderation of delta-9-tetrahydrocannabinol-induced effects on psychosis and cognition. Neuropsychopharmacology 31 (2006) 2748-2757
27. Howes O.D., Montgomery A.J., Asselin M.C., Murray R.M., Grasby P.M., and McGuire P.K. The pre-synaptic dopaminergic system before and after the onset of psychosis: initial results. Eur. Neuropsychopharmacol. 16 suppl 4 (2006) S177
28. Hulshoff Pol H.E., Hoek H.W., Susser E., Brown A.S., Dingemans A., Schnack H.G., van Haren N.E.M., Pereira Ramos L.M., Gispen-de Wied C.C., and Kahn R.S. Prenatal exposure to famine and brain morphology in schizophrenia. Am. J. Psychiatry 157 (2000) 1170-1172
29. Jones P., Rodgers B., Murray R., and Marmot M. Child developmental risk factors for adult schizophrenia in the British 1946 birth cohort. Lancet 344 (1994) 1398-1402
30. Kapur S. Psychosis as a state of aberrant salience: a framework linking biology, phenomenology, and pharmacology in schizophrenia. Am. J. Psychiatry 160 (2003) 13-23
31. Kellendonk C., Simpson E.H., Polan H.J., Malleret G., Vronskaya S., Winiger V., Moore H., and Kandel E.R. Transient and selective overexpression of dopamine D2 receptors in the striatum causes persistent abnormalities in prefrontal cortex functioning. Neuron 49 (2006) 603-615
32. Kuipers E., Garety P., Fowler D., Dunn G., Bebbington P., Freeman D., and Hadley C. London-East Anglia randomised controlled trial of cognitive-behavioural therapy for psychosis. I: effects of the treatment phase. Br. J. Psychiatry 171 (1997) 319-327
33. Laruelle M., Abi-Dargham A., van Dyck C.H., Gil R., D'Souza C.D., Erdos J., McCance E., Rosenblatt W., Fingado C., Zoghbi S.S., Baldwin R.M., Seibyl J.P., Krystal J.H., Charney D.S., and Innis R.B. Single photon emission computerized tomography imaging of amphetamine-induced dopamine release in drug-free schizophrenic subjects. Proc. Natl. Acad. Sci. 93 (1996) 9235-9240
34. Lewis D., David A., Andreasson S., and Allebeck P. Schizophrenia and city life. Lancet 340 (1992) 137-140
35. Li T., Stefansson H., Gudfinnsson E., Cai G., Liu X., Murray R.M., Steinthorsdottir V., Januel D., Gudnadottir V.G., Petursson H., Ingason A., Gulcher J.R., Stefansson K., and Collier D.A. Identification of a novel neuregulin 1 at-risk haplotype in Han schizophrenia Chinese patients, but no association with the Icelandic/Scottish risk haplotype. Mol. Psychiatry 9 (2004) 698-704
36. Lieberman J.A. Managing anticholinergic side effects. Prim. Care Companion J. Clin. Psychiatry 6 Suppl. 2 (2004) 20-23
37. Lieberman J.A., Perkins D., Belger A., Chakos M., Jarskog F., Boteva K., and Gilmore J. The early stages of schizophrenia: speculations on pathogenesis, pathophysiology, and therapeutic approaches. Biol. Psychiatry 50 (2001) 884-897
38. Maher B.A. A tentative theory of schizophrenic utterance. Prog. Exp. Pers. Res. 12 (1983) 1-52
39. Marcelis M., Navarro-Mateu F., Murray R., Selten J.P., and van Os J. Urbanization and psychosis: a study of 1942-1978 birth cohorts in The Netherlands. Psychol Med 28 (1998) 871-879
40. 158-met genotype and individual variation in the brain response to amphetamine. Proc. Natl. Acad. Sci. 100 (2003) 6186-6191
41. Mauri M.C., Volonteri L.S., De Gaspari I.F., Colasanti A., Brambilla M.A., and Cerruti L. Substance abuse in first-episode schizophrenic patients: a retrospective study. Clin. Pract. Epidemiol. Ment. Health 2 (2006) 4
42. McDonald C., Grech A., Toulopoulou T., Schulze K., Chapple B., Sham P., Walshe M., Sharma T., Sigmundsson T., Chitnis X., and Murray R.M. Brain volumes in familial and non-familial schizophrenic probands and their unaffected relatives. Am. J. Med. Genet. 114 (2002) 616-625
43. Millar J.K., Christie S., Semple C.A., and Porteous D.J. Chromosomal location and genomic structure of the human translin-associated factor X gene (TRAX; TSNAX) revealed by intergenic splicing to DISC1, a gene disrupted by a translocation segregating with schizophrenia. Genomics 67 (2000) 69-77
44. 2 receptors and cocaine self-administration. Nat. Neurosci. 5 (2002) 169-174
45. Mortensen P.B., Pedersen C.B., Westergaard T., Wohlfahrt J., Ewald H., Mors O., Andersen P.K., and Melbye M. Effects of family history and place and season of birth on the risk of schizophrenia. N. Engl. J. Med. 340 (1999) 603-608
46. Oner O., and Munir K. Attentional and neurocognitive characteristics of high-risk offspring of parents with schizophrenia compared with DSM-IV attention deficit hyperactivity disorder children. Schizophr. Res. 76 (2005) 293-299
47. Poulton R., Caspi A., Moffitt T.E., Cannon M., Murray R., and Harrington H. Children's self-reported psychotic symptoms and adult schizophreniform disorder: a 15-year longitudinal study. Arch. Gen. Psychiatry 57 (2000) 1053-1058
48. Schulze K., McDonald C., Frangou S., Sham P., Grech A., Toulopoulou T., Walshe M., Sharma T., Sigmundsson T., Taylor M., and Murray R.M. Hippocampal volume in familial and nonfamilial schizophrenic probands and their unaffected relatives. Biol. Psychiatry 53 (2003) 562-570
49. Schwab S.G., Knapp M., Mondabon S., Hallmayer J., Borrmann-Hassenbach M., Albus M., Lerer B., Rietschel M., Trixler M., Maier W., and Wildenauer D.B. Support for the association of schizophrenia with genetic variation in the 6p22.3 gene, dysbindin, in sib-pair families with linkage and in an additional sample of triad families. Am. J. Hum. Genet. 72 (2003) 185-190
50. Selten J.P., Veen N., Feller W., Blom J.D., Schols D., Camoenie W., Oolders J., van der Velden M., Hoek H.W., Rivero V.M., van der Graaf Y., and Kahn R. Incidence of psychotic disorders in immigrant groups to The Netherlands. Br. J. Psychiatry 178 (2001) 367-372
51. Sensky T., Turkington D., Kingdom D., Scott J.L., Scott J., Siddle R., O'Carroll M., and Barnes T.R.E. A randomized controlled trial of cognitive-behavioral therapy for persistent symptoms in schizophrenia resistant to medication. Arch. Gen. Psychiatry 57 (2000) 165-172
52. Shifman S., Bronstein M., Sternfeld M., Pisanté-Shalom A., Lev-Lehman E., Weizman A., Reznik I., Spivak B., Grisaru N., Karp L., Schiffer R., Kotler M., Strous R.D., Swartz-Vanetik M., Knobler H.Y., Shinar E., Beckmann J.S., Yakir B., Risch N., Zak N.B., and Darvasi A. A highly significant association between a COMT haplotype and schizophrenia. Am. J. Hum. Genet. 71 (2002) 1296-1302
53. Stefanis N.C., Delespaul P., Henquet C., Bakoula C., Stefanis C.N., and Van Os J. Early adolescent cannabis exposure and positive and negative dimensions of psychosis. Addiction 99 (2004) 1333-1341
54. Stefansson H., Sigurdsson E., Steinthorsdottir V., Bjornsdottir S., Sigmundsson T., Ghosh S., Brynjolfsson J., Gunnarsdottir S., Ivarsson O., Chou T.T., Hjaltason O., Birgisdottir B., Jonsson H., Gudnadottir V.G., Gudmundsdottir E., Bjornsson A., Ingvarsson B., Ingason A., Sigfusson S., Hardardottir H., Harvey R.P., Lai D., Zhou M., Brunner D., Mutel V., Gonzalo A., Lemke G., Sainz J., Johannesson G., Andresson T., Gudbjartsson D., Manolescu A., Frigge M.L., Gurney M.E., Kong A., Gulcher J.R., Petursson H., and Stefansson K. Neuregulin 1 and susceptibility to schizophrenia. Am. J. Hum. Genet 71 (2002) 877-892
55. Tang J.X., Zhou J., Fan J.B., Li X.W., Shi Y.Y., Gu N.F., Feng G.Y., Xing Y.L., Shi J.G., and He L. Family-based association study of DTNBP1 in 6p22.3 and schizophrenia. Mol. Psychiatry 8 (2003) 717-718 Erratum in: Mol. Psychiatry 8, 1008
56. Tarrier N., Beckett R., Harwood S., Baker A., Yusopoff L., and Ugarteburu I. A trial of two cognitive-behavioural methods of treating drug-resistant residual psychotic symptoms in schizophrenic patients. I. Outcome. Br. J. Psychiatry 162 (1993) 524-532
57. Tarrier N., Yusupoff L., Kinney C., McCarthy E., Gledhill A., Haddock G., and Morris J. Randomised controlled trial of intensive cognitive behaviour therapy for patients with chronic schizophrenia. BMJ. 317 (1998) 303-307
58. Turkington D., Kingdon D., and Weiden P.J. Cognitive behavior therapy for schizophrenia. Am. J. Psychiatry 163 (2006) 365-373
59. Valmaggia L.R., van der Gaag M., Tarrier N., Pijnenborg M., and Slooff C.J. Cognitive-behavioural therapy for refractory psychotic symptoms of schizophrenia resistant to atypical antipsychotic medication. Br. J. Psychiatry 186 (2005) 324-330
60. van den Bogaert A., Schumacher J., Schulze T.G., Otte A.C., Ohlraun S., Kovalenko S., Becker T., Freudenberg J., Jönsson E.G., Mattila-Evenden M., Sedvall G.C., Czerski P.M., Kapelski P., Hauser J., Maier W., Rietschel M., Propping P., Nöthen M.M., and Cichon S. The DTNBP1 (dysbindin) gene contributes to schizophrenia, depending on family history of the disease. Am. J. Hum. Genet. 73 (2003) 1438-1443
61. van Os J., Bak M., Hanssen M., Bijl R.V., de Graaf R., and Verdoux H. Cannabis use and psychosis: a longitudinal population-based study. Am. J. Epidemiol. 156 (2002) 319-327
62. Weiser M., Knobler H.Y., Noy S., and Kaplan Z. Clinical characteristics of adolescents later hospitalized for schizophrenia. Am. J. Med. Genet. 114 (2002) 949-955
63. Zammit S., Allebeck P., Andreasson S., Lundberg I., and Lewis G. Self reported cannabis use as a risk factor for schizophrenia in Swedish conscripts of 1969: historical cohort study. BMJ. 325 (2002) 1199